Evidence map›Paper›PMID 16014900›Full record

ReviewJournal of virology2005

Stealth and cunning: hepatitis B and hepatitis C viruses.

Stefan F Wieland, Francis V Chisari

Abstract readComparative StudyReview
In one paragraph

Review in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 211 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
211citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

211 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. KASL clinical practice guidelines: management of hepatitis C.Clinical and molecular hepatology · 2016
    Guideline
  2. KASL clinical practice guidelines: management of hepatitis C.Clinical and molecular hepatology · 2014
    Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Article
  10. Paradox of hepatitis B: Metabolic risk and cardiovascular protection in a national cohort.International journal of cardiology. Cardiovascular risk and prevention · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

151 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stefan F WielandDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
Francis V Chisari

Funding

PATHOGENESIS OF HEPATITIS B VIRUS IN TRANSGENIC MICER01CA040489 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI CHISARI, FRANCIS VINCENT · 1985 to 2010
$7.7M
PATHOGENESIS OF LIVER DISEASE IN HEPATITISR01AI020001 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CHISARI, FRANCIS VINCENT · 1985 to 2012
$7.4M
HEPATITIS C VIRUS IMMUNOBIOLOGY AND PATHOGENESISR01CA076403 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI CHISARI, FRANCIS VINCENT · 1998 to 2007
$4.0M
PATHOGENESIS OF HEPATITIS B IN TRANSGENIC MICER37CA040489 · NCI · SCRIPPS RESEARCH INSTITUTE · PI CHISARI, FRANCIS VINCENT · 1990 to 1999
–
NCI NIH HHS CA40489NCI NIH HHS CA76403NCI NIH HHS R01 CA040489NCI NIH HHS R01 CA076403NCI NIH HHS R37 CA040489NIAID NIH HHS AI20001NIAID NIH HHS R01 AI020001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsHepacivirusHepatitis BHepatitis B virusHepatitis CHumansImmunity, ActiveImmunity, InnateMutationPan troglodytesVirus Replication

Identifiers

PMID16014900
PMCPMC1181548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.